FOXO3 and colorectal carcinoma: EGFR combined with prion protein was found to activate both KLF5 and Forkhead Box O3 (FOXO3a), a downstream effector of EGFR and the PI3K pathway, thereby inducing cisplatin resistance in aggressive CRC.